Abstract
Erythropoietin (EPO) is a multi-functional cytokine, which exerts erythropoietic effects but also carries anti-apoptotic and immune-modulatory activities upon binding to two distinct receptors which are expressed on erythroid, parenchymal and immune cells, respectively. Whereas EPO ameliorates hemolytic anemia in malaria or trypanosomiasis and improves the course of autoimmune diseases such as inflammatory bowel disease or autoimmune encephalomyelitis, it deleteriously inhibits macrophage functions in Salmonella infection in animal models. Thus, the specific modulation of extra-erythropoietic EPO activity forms an attractive therapeutic target in infection and inflammation.
Copyright © 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anemia, Hemolytic / genetics
-
Anemia, Hemolytic / pathology
-
Anemia, Hemolytic / therapy
-
Animals
-
Cell Hypoxia
-
Erythropoiesis / genetics
-
Erythropoietin / genetics
-
Erythropoietin / immunology
-
Erythropoietin / metabolism*
-
Erythropoietin / therapeutic use
-
Genetic Pleiotropy*
-
Host-Pathogen Interactions*
-
Humans
-
Hypoxia-Inducible Factor 1, alpha Subunit / immunology
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Inflammation / immunology
-
Inflammation / metabolism*
-
Macrophages / immunology
-
Mice
-
NF-kappa B / immunology
-
NF-kappa B / metabolism
-
Salmonella / immunology
-
Salmonella / pathogenicity
-
Salmonella Infections / immunology
-
Salmonella Infections / microbiology
-
Signal Transduction*
Substances
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
NF-kappa B
-
Erythropoietin